Home › Compare › AETLF vs ABBV
AETLF yields 9523.81% · ABBV yields 3.06%● Live data
📍 AETLF pulled ahead of the other in Year 1
Combined, AETLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AETLF + ABBV for your $10,000?
Aeris Environmental Ltd, together with its subsidiaries, engages in the research, development, and commercialization of proprietary technologies in Australia and internationally. The company offers heating, ventilation, air-conditioning, and refrigeration (HVAC/R) hygiene and remediation technology, indoor air quality, and corrosion protection services, as well as distributes HVAC/R hygiene, anti-corrosion, and disinfectant products. It also provides building/industrial, corporate/retail, corrosion protection, flood remediation, government/education, health/aged care, home/residential, HVAC and R, manufacturing/equipment, mould and odour control, specialty, surface cleaning and disinfection, and surface hygiene products, as well as accessories. In addition, the company offers indoor air quality assessments, mould investigations and sampling, in-house nonviable microscopy analysis, mould remediation management, post remediation verification and occupational clearance, building water ingress assessments and rectification, duct cleaning and AHU servicing management, and infection control and containment services. It provides its solutions to manufacturing and equipment, building and industrial, health and aged care, government and education, corporates and retail, and home and residential customers. The company was incorporated in 2000 and is based in Rosebery, Australia.
Full AETLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.